Dyne Therapeutics (NASDAQ:DYN) Shares Gap Down - Should You Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN - Get Free Report)'s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $13.82, but opened at $12.51. Dyne Therapeutics shares last traded at $11.50, with a volume of 1,211,013 shares.

Wall Street Analysts Forecast Growth

DYN has been the subject of a number of research reports. HC Wainwright reduced their target price on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a report on Friday, May 9th. JPMorgan Chase & Co. reduced their target price on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating for the company in a report on Friday, March 21st. Chardan Capital restated a "buy" rating and issued a $50.00 price target on shares of Dyne Therapeutics in a research report on Tuesday. Robert W. Baird reduced their price target on shares of Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating for the company in a research report on Wednesday. Finally, Raymond James Financial assumed coverage on shares of Dyne Therapeutics in a research report on Wednesday, June 11th. They issued an "outperform" rating and a $37.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $43.93.

Dyne Therapeutics Trading Down 0.7%

The company has a market cap of $1.23 billion, a PE ratio of -3.00 and a beta of 1.16. The business's 50-day simple moving average is $11.46 and its 200-day simple moving average is $14.84.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). On average, research analysts predict that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Rhumbline Advisers raised its holdings in shares of Dyne Therapeutics by 4.2% during the 1st quarter. Rhumbline Advisers now owns 133,627 shares of the company's stock valued at $1,398,000 after purchasing an additional 5,383 shares in the last quarter. Optimize Financial Inc bought a new position in shares of Dyne Therapeutics during the 1st quarter valued at $154,000. Exome Asset Management LLC bought a new position in shares of Dyne Therapeutics during the 1st quarter valued at $2,703,000. Caxton Associates LLP bought a new position in Dyne Therapeutics in the 1st quarter worth $157,000. Finally, Voleon Capital Management LP bought a new position in Dyne Therapeutics in the 1st quarter worth $624,000. Institutional investors own 96.68% of the company's stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.